The Filing Desk

Rapid Micro Biosystems

RPID · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

RPID · Last close · November 19, 2026
$0.74
Value Rapid Micro Biosystems yourself

Rapid Micro Biosystems' revenue rose 19.7% to $34 million in fiscal 2025. Its operating margin was −141.1%, up from −178.0% a year earlier. Free cash flow was −$32 million. The diluted share count rose 2.5%.

Rapid Micro Biosystems, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 12, 2026 · 0001380106-26-000034 Updated
Revenue
$34M
19.7%
Operating margin
−141.1%
36.9 pts
Net income
−$47M
 
Free cash flow
−$32M
 
Return on capital
−192.8%
38.4 pts
Market cap
$36M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Rapid Micro Biosystems lost money in fiscal 2025: a net loss of $47 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments194109925138
Debt incl. finance leases000019
Net debt (negative means net cash)−194−108−92−50−19
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x0.6x
Interest coverage−17.8x−1,505.2x−1,488.5x−1,248.0x−43.5x
Current ratio12.0x7.3x6.3x4.6x3.3x
Quick ratio11.1x6.2x5.3x3.5x2.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Rapid Micro Biosystems' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Rapid Micro Biosystems shares on the open market, and 5 insiders sold $1.1 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Mar 11, 2026John J. Addington WilsonChief Operating OfficerSold9,603$4.32$41,485Form 4
Mar 11, 2026Sean M WirtjesChief Financial OfficerSold7,480$4.32$32,314Form 4
Mar 10, 2026Robert G. Spignesi Jr.President and CEO, DirectorSold17,922$4.11$73,659Form 4
Feb 20, 2026Sean M WirtjesChief Financial OfficerSold17,254$3.92$67,636Form 4
Feb 20, 2026John J. Addington WilsonChief Operating OfficerSold5,403$3.92$21,180Form 4
Feb 19, 2026Robert G. Spignesi Jr.President and CEO, DirectorSold38,327$3.89$149,092Form 4
Feb 9, 2026Robert G. Spignesi Jr.President and CEO, DirectorSold12,840$3.78$48,535Form 4
Feb 9, 2026Sean M WirtjesChief Financial OfficerSold6,027$3.78$22,782Form 4
Feb 9, 2026John J. Addington WilsonChief Operating OfficerSold4,610$3.78$17,426Form 4
Feb 4, 2026Longitude Venture Partners II L.P.10% ownerSold49,000$3.88$190,120Form 4
Feb 3, 2026Longitude Prime Partners LLC10% ownerSold27,500$4.24$116,600Form 4
Feb 2, 2026Longitude Prime Partners LLC10% ownerSold27,500$4.25$116,875Form 4
The latest 12 of 14 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score2 of 82 of 82 of 8
Rule of 40−176.9%−137.7%−75.3%
Altman Z''−2.88−11.50−22.43
Accruals ratio−4.4%−2.3%−18.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassPass
F-score2 of 82 of 82 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Rapid Micro Biosystems side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Rapid Micro BiosystemsFY2519.7%−141.1%−95.0%−192.8%—2
MaxCyteFY25−14.5%−157.1%−109.5%———Compare
Bionano GenomicsFY25−7.4%−117.0%−57.3%−89.9%—5Compare
Alpha TeknovaFY257.3%−41.9%−24.2%−22.0%—5Compare
PrecipioFY2529.8%−5.0%1.5%−7.8%−37.4x7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue162317222834
Revenue growth—44.5%−26.2%31.4%24.6%19.7%
Gross profit——————
Research and development61013131514
Operating income−30−47−63−57−50−47
Net income−37−74−61−52−47−47
Diluted EPS (US$)−126.11−3.94−1.43−1.22−1.08−1.05
Diluted shares (millions)02042434445
Cash flow
Cash from operations−31−55−58−45−44−31
Capital expenditure137211
Free cash flow−32−58−65−47−46−32
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation024544
Balance sheet at fiscal year end
Cash and short-term investments45194109925138
Debt incl. finance leases25000019
Total assets702411911449875
Total liabilities452026262342
Shareholders' equity−1272211641187533
Margins and ratios
Gross margin——————
Operating margin−190.0%−203.3%−369.0%−251.2%−178.0%−141.1%
Net margin−230.6%−316.5%−354.9%−233.0%−167.2%−140.3%
Free cash flow margin−197.1%−250.4%−381.1%−208.4%−162.3%−95.0%
Rule of 40 (growth + FCF margin)—−205.9%−407.3%−176.9%−137.7%−75.3%
Return on capital——−119.8%−108.8%−154.4%−192.8%
Return on equity—−156.5%−31.6%−37.2%−48.5%−86.8%
Return on assets—−47.3%−28.2%−31.4%−38.8%−54.5%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Rapid Micro Biosystems' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Rapid Micro Biosystems.